The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

For example, on a recent episode of the Just Trish podcast, singer, songwriter and rapper Lizzo explained that she tried Ozempic and other GLP-1 drugs at one point in her “weight release” journey but ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

With its new serum, the medical grade skin care brand is targeting laxity, which many weight loss drug users experience.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...